Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Third Quarter (Q3) and Nine Months ended September 30, 2021
Issued Date: October 27, 2021
GSK reported strong Q3 sales growth driven by commercial execution and underlying demand across Pharmaceuticals, Vaccines, and Consumer Healthcare. The company continues to advance its strategy to demerge its Consumer Healthcare business in mid-2022, creating a new world-leading biopharma company (New GSK) focused on the immune system, genetics, and advanced technologies.
Key Financial Metrics
| Metric | Q3 2021 (£m) | Q3 2020 (£m) | Growth (AER%) | Growth (CER%) |
|---|---|---|---|---|
| Turnover | 9,077 | 8,646 | +5% | +10% |
| Total Operating Profit | 1,938 | 1,858 | +4% | +15% |
| Adjusted Operating Profit | 2,874 | 2,665 | +8% | +16% |
| Total EPS | 23.3p | 25.0p | -7% | +3% |
| Adjusted EPS | 36.6p | 35.6p | +3% | +10% |
| Net Cash from Operations | 2,562 | 861 | >100% | N/A |
| Free Cash Flow | 1,223 | (180) | >100% | N/A |
Segment Performance (Q3 2021):
- Pharmaceuticals: £4.4 billion (+5% AER, +10% CER). Growth driven by New and Specialty medicines (+24% CER), Respiratory (+33% CER), and Oncology (+34% CER). COVID-19 solution Xevudy contributed £114 million.
- Vaccines: £2.2 billion (+7% AER, +13% CER). Shingrix sales reached £502 million (+41% CER). Pandemic adjuvant sales were £94 million.
- Consumer Healthcare: £2.5 billion (+3% AER, +8% CER). Excluding divestments/brands under review, growth was +10% CER.
Balance Sheet (as of Sept 30, 2021):
- Net Debt: £22.1 billion (Gross debt £25.6 billion; Cash and liquid investments £3.5 billion).
- Net Assets: £21.7 billion.
Material Changes vs. Prior Period
Revenue and Profit: Q3 turnover increased 10% at constant exchange rates (CER), primarily due to strong growth in New and Specialty pharmaceuticals and pandemic-related sales. Adjusted operating margin improved to 31.7% (up 1.5 percentage points CER) due to cost discipline and favorable mix, despite increased R&D investment.
EPS Impact: Total EPS declined 7% AER due to higher impairments and lower milestone/disposal income, partially offset by lower restructuring charges. Adjusted EPS grew 10% CER, with COVID-19 solutions contributing approximately 5% to growth.
Cash Flow: Net cash from operating activities surged to £2.6 billion (from £0.9 billion in Q3 2020), driven by increased operating profit, decreased inventory, and favorable timing of taxes and rebates. Free cash flow turned positive at £1.2 billion compared to an outflow of £0.2 billion in the prior year.
Divestments and Restructuring: Major restructuring charges decreased to £131 million in Q3 2021 from £336 million in Q3 2020. The company continues to prepare for the separation of Consumer Healthcare, with separation costs of £75 million incurred in the quarter.
Guidance, Outlook, and Risks
2021 Full Year Guidance (Updated):
- Adjusted EPS: Expected to decline between -2% and -4% at CER, excluding COVID-19 solutions. This is an improvement from the previous guidance of a mid-to-high single-digit decline.
- COVID-19 Solutions Contribution: Expected to contribute 7% to 9% to Adjusted EPS at CER for the full year (previously 4% to 6%).
- Revenue Outlook:
- Pharmaceuticals: Low-single digit growth at CER (previously flat to low-single digit).
- Vaccines: Mid-single digit decline at CER (previously broadly flat), reflecting disruption from COVID-19 vaccination prioritization impacting Shingrix.
- Consumer Healthcare: Low to mid-single digit growth at CER (excluding divested brands).
2022 Outlook: Management reaffirmed expectations for meaningful improvement in revenues and margins in 2022. The 2022 outlook excludes any contribution from COVID-19 solutions.
Dividends: A third interim dividend of 19p per share was declared for Q3 2021. The company expects a full-year 2021 dividend of 80p per share. For 2022, the aggregate dividend across the two new businesses is expected to be 55p per share (a 31% decrease from 2021), reflecting the new capital allocation framework for New GSK.
Risks and Contingencies:
- COVID-19 Pandemic: Ongoing disruption to routine adult vaccinations (specifically Shingrix) due to government prioritization of COVID-19 programs. Uncertainty remains regarding the duration and severity of the pandemic's impact on trading results and clinical trials.
- Exchange Rates: Strengthening Sterling against the US Dollar, Euro, and Yen negatively impacted reported growth. If period-end rates hold for the rest of 2021, the estimated negative impact on 2021 Sterling turnover growth would be 5%.
- Legal Matters: Aggregate provision for legal and other disputes was £0.2 billion. No significant legal developments occurred in the quarter, but ultimate liability may vary.
Investor Verification Checklist
- COVID-19 Sustainability: Verify the durability of sales from Xevudy and pandemic adjuvants, as these are temporary revenue drivers excluded from long-term 2022 guidance.
- Shingrix Recovery: Monitor US prescription trends for Shingrix to confirm the anticipated recovery in H2 2021 and 2022 following pandemic-related disruptions.
- Demerger Progress: Track the timeline and regulatory approvals for the mid-2022 separation of the Consumer Healthcare business, which impacts future dividend policy and capital allocation.
- Contingent Consideration: Review the fair value movements of the ViiV Healthcare contingent consideration liability (£5.2 billion), which significantly impacts Total EPS but is excluded from Adjusted EPS.
- Pharmaceutical Pipeline: Assess the progress of key late-stage assets, including cabotegravir for HIV prevention (FDA decision expected Jan 2022) and daprodustat for anaemia.